|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the cognitive profile of healthy individuals with increased Cardiovascular Risk Factors, Aging and Dementia (CAIDE) dementia risk score and to explore whether this association is related to vascular burden and CSF biomarkers of amyloidosis and neurodegeneration.
|
29898969 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
No association of ARHL with CSF or brain Aβ levels was found.
|
31118310 |
2019 |
|
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This may indicate that Aβ levels in the CSF are affected significantly by ventriculomegaly and not as much by pathophysiological pathways characteristic for each dementia entity.
|
29324921 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To perform a meta-analysis of 4 core CSF biomarkers (β-amyloid [Aβ]42, Aβ40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA).
|
29386280 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker- the CSF total tau/Aβ ratio.
|
28800330 |
2017 |
|
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
|
29523644 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When using the core CSF biomarkers (Aβ42, total Tau and phosphorylated Tau), 30% of the patients fell into the high-AD-likelihood (HL) group (both amyloid and neurodegeneration markers positive), 30% into the low-AD-likelihood group (all biomarkers negative), 28% into the suspected non-Alzheimer pathophysiology (SNAP) group (only neurodegeneration markers positive) and 12% into the isolated amyloid pathology group (only amyloid-positive).
|
29558986 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.
|
29171991 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of Aβ and tau imaging in AD brain and CSF as well as blood biomarkers is shortly summarized.
|
30605056 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence.
|
31388720 |
2020 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, episodic disturbances can diminish CSF cerebral flow circulation increasing deposition in cerebral parenchyma of contrary metabolic products (e.g. beta Amyloid), possibly having a causal influence on senile dementia.
|
30037601 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) biomarkers amyloid-β1-42 peptide (Aβ1-42) and tau were used in order to differentiate AD from SNAP.
|
31201430 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We secondarily hypothesized a third group characterized by either CSF tau pathology or neurodegeneration, in addition to amyloidosis (A+/N+ or Stage 2), would show lower neuropsychology scores than the amyloid positive group (A+/N- or Stage 1) when compared to the amyloid negative group.
|
28497179 |
2017 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared CSF levels of biomarkers of amyloidosis (Aβ<sub>1-42</sub>) and neurodegeneration (p-Tau<sub>181</sub>) in individuals with aMCI and with subjective cognitive impairment (SCI) in order to ascertain diagnostic accuracy and predict the odds ratio associated with aMCI.
|
29017912 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients were classified as normal, amyloidosis (A+/N-), amyloidosis and neurodegeneration (A+/N+) or suspected non-AD pathophysiology (SNAP), according to their CSF levels of biomarkers.
|
29966201 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to such hypothesis, this cross-sectional study tested, in PD patients, the association between levels of PA and well-known risk factors for PDD, such as mood disorders and amyloid-β42 CSF content.
|
30746564 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, 51 patients (n = 32 mild cognitive impairment/mild dementia-AD, n = 19 moderate/severe dementia-AD) diagnosed according to clinical-biological criteria (CSF biomarkers and amyloid-PET) and 29 controls (with negative amyloid-PET) underwent neuropsychological and 3T-MRI examinations.
|
31491594 |
2019 |
|
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The potential for E22P-Aβ as a CSF biomarker of cerebral Aβ plaques should be investigated.
|
31688040 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed whether these polymorphisms are associated with cerebrospinal fluid AD biomarkers including total tau (t-tau), phosphorylated tau proteins (p-tau181, p-tau199, and p-tau231), amyloid-β42 (Aβ42), and visinin-like protein 1 (VILIP-1) to test possible relationships of specific genotypes and pathological levels of CSF AD biomarkers.
|
31771069 |
2020 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF proteins associated with AD clinical stages and progression can complement Aβ and tau markers to inform neurodegeneration.
|
30253800 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic models were constructed by Cox proportional hazards regression with patient characteristics (age, sex, and Mini-Mental State Examination [MMSE] score), magnetic resonance imaging (MRI) biomarkers (hippocampal volume, normalized whole-brain volume), cerebrospinal fluid (CSF) biomarkers (amyloid-β1-42, tau), and combined biomarkers.
|
29049480 |
2017 |
|
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.
|
30365556 |
2018 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined whether neuropsychiatric symptoms (NPS) interact with cerebrospinal fluid (CSF) biomarkers (amyloid-β42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, and ptau181/Aβ42) of Alzheimer's disease pathology to predict driving decline among cognitively-normal older adults (N = 116) aged ≥65.
|
28453487 |
2017 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither amyloid-PET nor CSF biomarkers could discriminate short-term converters from non-converters.
|
30927601 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The core AD cerebrospinal fluid (CSF) biomarker toolbox include amyloid β (Aβ42 and the Aβ42/40 ratio) reflecting brain amyloidosis, total tau (T-tau) reflecting neurodegeneration intensity, and phosphorylated tau (P-tau) that is related to tau pathology.
|
31699324 |
2019 |